Evoke Pharma is a pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. Co. is developing Gimoti (metoclopramide) nasal spray, a nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Diabetic gastroparesis is a GI disorder, in which food in an individual's stomach takes too long to empty resulting in a variety of GI symptoms and systemic metabolic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. The EVOK stock yearly return is shown above.
The yearly return on the EVOK stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the EVOK annual return calculation with any dividends reinvested as applicable (on ex-dates).
|